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In people living with HIV (PLWH), immune compromise is largely due to a decrease in 
CD4+ T-lymphocyte (CD4) cells, resulting in increased rates of human immunodeficiency 
virus (HIV)-associated morbidity and mortality as CD4+ cell count declines. Previously, it 
was common to defer initiation of antiretroviral therapy (ART) in asymptomatic PLWH until 
their CD4+ cell count declined below a certain threshold, which has changed throughout the 
years based on updated guidelines, increasing access to ART, and lower drug prices. There is 
increasing evidence that early initiation of combination ART/ highly-active ART offers 
benefit even in individuals with relatively high CD4+ cell counts, as demonstrated in trials 
such as the Strategic Timing of Antiretroviral Treatment (START) study (1) and Temprano 
study (2).
The START trial was a randomized controlled trial that enrolled PLWH with a CD4+ cell 
count greater than 500 cell/μL. The primary endpoint was any serious AIDS-related event, 
serious non-AIDS related event, or death from any cause. The findings in this trial showed 
that the primary endpoint occurred in significantly fewer individuals who were started 
immediately on ART rather than when their CD4+ cell count dropped below 350 cell/μL. 
Furthermore, more than two-thirds of primary end points occurred in PLWH with a CD4+ 
cell count over 500 cells/μL. The Temprano study was a 2-by-2 factorial, 1:1 superiority trial 
that enrolled PLWH with a CD4+ cell count less than 800 cells/μL. Participants were 
enrolled into one of four treatment groups: deferred ART based on country-specific WHO 
criteria at the time of the study, deferred ART plus 6-month isoniazid preventive therapy 
(IPT), early/immediate ART initiation, and early/immediate ART plus 6-month of IPT. The 
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primary end point was a composite of AIDS-related diseases, non-AIDS-defining cancer, 
non-AIDS-defining invasive bacterial disease, or death from any cause. The risk of death or 
severe HIV-related illness was independently lower in the early ART and IPT groups 
compared to the deferred ART and non-IPT groups.
As a result of these studies and others, there is widespread consensus that PLHW should be 
started on ART as soon as possible after HIV diagnosis to prevent unnecessary morbidity 
and mortality associated with deferred ART initiation. In addition, Temprano provided 
evidence that IPT can help prevent tuberculosis-related morbidity and mortality Although 
most AIDS-related deaths occur in PLWH with a CD4+ cell count <350 cells/μL, the results 
of these trials show that PLWH on ART with higher CD4+ cell counts still experience 
significant morbidity and mortality from both infectious and non-infectious causes. The 
CD4+ cell count and HIV RNA measurement (HIV viral load or VL) continue to be the two 
most commonly-used markers for monitoring immune recovery and treatment effectiveness 
for individuals on ART, but increasing evidence shows that these markers are insufficient for 
prognosis of non-AIDS related morbidity and mortality in individuals virally suppressed on 
ART. Are there other markers that may help predict morbidity and mortality in this 
population?
CD8+ T-lymphocyte (CD8+) cell counts increase in response to acute infection and remain 
raised in HIV and other chronic infections. The CD4:CD8 ratio naturally decreases with age, 
is associated with increased mortality, and is a marker of both acute and chronic 
inflammation (3). Thus, it has been suggested that both CD8+ cell count and CD4:CD8 ratio 
may be additional prognostic markers for morbidity and mortality in PLWH. Prior to ART 
initiation the combined CD4+ and CD8+ T-lymphocyte levels remain near constant, with a 
gradual decline of CD4+ cells and increase in CD8+ cells until the transition from HIV 
infection to AIDS, where a sharp decline in both CD4+ and CD8+ cells is observed (4). After 
initiation of ART, a negative correlation between changes in CD4+ and CD8+ cell count has 
been observed (5) with an increase in CD4+ cell count and decrease in CD8+ cell count. This 
suggests that a declining CD8+ cell count or increasing CD4:CD8 ratio along, with 
undetectable HIV VL, could be markers for effective antiretroviral treatment and a good 
prognosis.
In a recent issue of Clinical Infectious Diseases, Trickey et al. report on their investigation 
into whether CD4:CD8 ratio or CD8+ cell count is independently associated with all-cause, 
AIDS, and non-AIDS-related mortality in PLWH on ART with suppressed HIV VL and 
CD4+ cell count ≥350 cells/μL (3). They used data from the Antiretroviral Therapy Cohort 
Collaboration (ART-CC), a collection of 13 European and North American cohorts of 
PLWH. Eligible participants were enrolled between 1996 and 2010, had to be ART-naive, 
and were aged ⩾16 years of age when they started on ART with at least three antiretroviral 
drugs. Follow-up began after ART initiation when the participant’s CD4+ cell count first 
reached 350 cells/μL or greater, a CD8+ cell count was first recorded, and HIV VL was <200 
copies/μL or undetectable.
Primary outcomes were all-cause and cause-specific mortality hazard ratios for tertiles of 
CD4:CD8 ratio [0–0.40, 0.41–0.64 (reference), >0.64], CD8+ cell count [0–760, 761–1,138 
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(reference), >1,138 cells/μL], and the shape of associations using cubic spines. Cause of 
death was determined by ICD-10 codes or free text, and for the latter classification two 
clinicians independently classified each death. If the cause of death could not be concluded 
from ICD-10 codes or free test, deaths were labeled as “unclassifiable”, and if the cause of 
death was unknown, these deaths were labeled as “unknown”. Deaths due to an AIDS-
defining condition and/or that occurred when there was a CD4+ cell count <100 cells/μL 
were classified as AIDS-related. All other deaths, excluding “unknown” deaths, were 
considered to be non-AIDS related.
For all individuals at 10 years, after initiation of ART mean CD8+ cell count declined from 
1,040 cells/μL at baseline to 942 cells/μL at 1 year and plateaued around 930 cells/μL, which 
is above the range of 209–924 cells/μL which is considered normal in the general population 
(6). Mean CD4+ cell count increased steadily from 507 to 678 cells/μL at 10 years; mean 
CD4:CD8 ratio increased from 0.49 at baseline to 0.58 at 1 year, then more gradually to 0.73 
after 10 years, still significantly lower than the mean CD4:CD8 ratio of 1.8 in the general 
population (6).
CD8+ cell counts showed a U-shaped association with all-cause mortality, with the lowest 
mortality rates near the median CD8+ cell count value and the highest rates at the CD8+ cell 
count extremes. The highest all-cause mortality rate was associated with the highest CD8+ 
cell counts. This association was statistically significant but not prognostic for all-cause 
mortality; CD4:CD8 ratio showed no association with all-cause mortality. Similarly, CD8+ 
cell count had a U-shaped association with non-AIDS-related mortality, but this was neither 
statistically significant nor prognostic. There was no association with CD4:CD8 ratio and 
non-AIDS-related mortality. Conversely, CD8+ cell count and CD4:CD8 ratio were both 
associated with AIDS-related mortality to a statistically-significant degree (P=0.016 and 
0.037, respectively). AIDS-related mortality declined with increasing CD4:CD8 ratio and 
with decreasing CD8+ cell count. The upper tertiles of both CD4:CD8 ratio and CD8+ cell 
count were both prognostic for AIDS-related deaths. The adjusted hazard ratio (aHR) for 
AIDS-related mortality for the lowest versus middle (reference) tertile of CD4:CD8 ratio 
was 1.28 (95% CI, 0.95–1.73); the aHR for the highest versus middle tertile of CD8+ cell 
count was 1.36 (95% CI, 1.01–1.84). Both CD4:CD8 ratio and CD8+ cell count were 
prognostic for AIDS-related deaths to a statistically significant degree.
Thus, neither CD4:CD8 ratio nor CD8+ cell count showed any prognostic ability to predict 
all-cause mortality in PLWH in this population. This study had a sample size of almost 
50,000 individuals, which was significantly larger when compared to previous studies. 
Individuals included in this study came from a wide range of countries across a variety of 
high-resource settings, so these findings are likely to be generalizable to similar settings. 
Although the study authors found that CD4:CD8 ratio and CD8+ cell count were not 
prognostic for all-cause mortality, there were other interesting observations from this study. 
Both low CD4:CD8 ratio and high CD8+ cell count were associated with increased all-cause 
mortality, suggesting that there was excessive AIDS-related mortality in a population with 
suppressed HIV VL and relatively high CD4+ cell counts. Furthermore, CD8+ cell count 
decreased sharply after ART initiation but remained elevated at a baseline above that of a 
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general population. This suggests a need for early HIV diagnosis and ART initiation before 
the CD8+ cell count elevates to levels that may be difficult to recover from.
Hoenigl et al. analyzed CD4/CD8 ratios in 90 individuals diagnosed with acute HIV 
infection (AHI) between 2007–2014 in relation to (I) signs and symptoms of AHI and (II) 
early versus delayed antiretroviral initiation (7). They found that CD4/CD8 ratios were 
significantly lower in those reporting signs and symptoms of AHI at the time of HIV 
diagnosis compared to those who did not report symptoms. In addition, lower CD4/CD8 
ratios were associated with a longer duration of signs and symptoms of AHI and were 
observed in those who sought medical attention for their symptoms. Lastly, very early ART 
initiation (within 40 days of estimated date of infection) was associated with a significant 
increase compared to delayed ART initiation (greater than 40 days since estimated date of 
infection). Thus, very early ART initiation may lead to a greater increase in CD4/CD8 ratios.
We still have much to learn regarding why PLWH with reconstituted immunity still suffer 
greater morbidity and mortality from both infectious and non-infectious causes than the 
general population. Although CD8+ cell count appears to be a marker for chronic 
inflammation, this biomarker alone does not appear to reliably prognosticate non-AIDS 
related mortality in PLWH. Further investigation into the pathogenesis of chronic 
inflammation associated with HIV, better candidate biomarkers to diagnose this, and better 
treatment options are all clearly warranted.
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